Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

COX-2s Left Out Of Drug Classes, Will Go Up Against Other NSAIDs

This article was originally published in The Pink Sheet Daily

Executive Summary

COX-2 inhibitors are among the drugs where Medicare coverage would be "recommended," but not required, under the U.S. Pharmacopeia's model formulary
Advertisement

Related Content

CMS Medicare Formulary Standards Will Have More “Granularity” Than USP
CMS Medicare Formulary Standards Will Have More “Granularity” Than USP
USP Draft Medicare Formulary Sets 146 Drug Categories And Classes
USP Draft Medicare Formulary Sets 146 Drug Categories And Classes
Cardiovascular Category Has 11 Classes, But Statins Not Among Them
USP Draft Medicare Formulary Sets 146 Drug Categories And Classes

Topics

Advertisement
UsernamePublicRestriction

Register

PS060330

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel